Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Apr. 1, 2024-- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that, effective April 1, 2024, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 139,453 shares of its common stock and 23,698 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan.
波士頓--(美國商業資訊)--2024年4月1日--致力於發現和交付下一代精準抗癌藥物的臨床階段生物技術公司Tango Therapeutics, Inc.（納斯達克股票代碼：TNGX）今天宣佈，自2024年4月1日起，Tango Therapeutics董事會薪酬委員會授予了購買其139,453股普通股和23,698股限制性股票的非合格股票期權根據Tango Therapeutics的2023年激勵計劃，向新員工提供單位（RSU）。
The Tango Therapeutics 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual's entering into employment with Tango Therapeutics, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
根據納斯達克上市規則第5635（c）（4）條，Tango Therapeutics2023年激勵計劃專門用於向個人發放股權獎勵，以此作爲此類個人在Tango Therapeutics工作的激勵材料。
The options have an exercise price of $7.64 per share, which is equal to the closing price of Tango Therapeutics' common stock on April 1, 2024. Each option will vest as to 25% of the shares underlying such option on the first anniversary of the employee's start date and as to an additional 1/36th of the remaining shares underlying the option monthly thereafter, in each case, subject to each such employee's continued employment on each vesting date. The RSU award will vest in three equal annual installments, subject to the employee's continued employment on each vesting date. The options and RSUs are subject to the terms and conditions of Tango Therapeutics' 2023 Inducement Plan, which was approved in February 2023, and the terms and conditions of the stock option and RSU agreements covering the grant.
這些期權的行使價爲每股7.64美元，等於Tango Therapeutics普通股在2024年4月1日的收盤價。每種期權將在員工入職一週年之際授予該期權標的25％的股份，此後每月再授予該期權所依據的剩餘股份的1/36，在每種情況下，視每位員工在每個歸屬日的持續就業情況而定。RSU獎勵將分三次等額的年度分期發放，視員工在每個授予日期的持續就業情況而定。期權和限制性股票單位受2023年2月批准的Tango Therapeutics2023年激勵計劃的條款和條件以及涵蓋該贈款的股票期權和限制性股份協議的條款和條件的約束。
About Tango Therapeutics
關於探戈療法
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. For more information, please visit www.tangotx.com.
Tango Therapeutics是一家處於臨床階段的生物技術公司，致力於發現新的藥物靶點並提供用於治療癌症的下一代精準醫療。Tango使用一種以患者爲起點和終點的方法，利用合成致死性的遺傳原理來發現和開發針對癌症關鍵靶點的療法。這包括將精準腫瘤靶標的領域擴展到新的領域，例如腫瘤抑制劑基因丟失及其對癌細胞逃避免疫細胞殺傷能力的貢獻。欲了解更多信息，請訪問 www.tangotx.com。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240401007671/en/
Investor Contact:
Sam Martin/Andrew Vulis
Argot Partners
tango@argotpartners.com
Media Contact:
Amanda Brown Galgay
SVP, Corporate Communications, Tango Therapeutics
media@tangotx.com
投資者聯繫人：
山姆·馬丁/安德魯·弗利斯
Argot Par
tango@argotpartners.com
媒體聯繫人：
阿曼達·布朗·加爾蓋
Tango Therapeutics 企業傳播高級副總裁
media@tangotx.com
Source: Tango Therapeutics, Inc.
資料來源：Tango Therapeutics, Inc.
譯文內容由第三人軟體翻譯。